RECURSION PHARMACEUTICALS, INC. Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security of $4.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2026-06-30 was $2.25M, a 8.01% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2026-03-31 was $2.21M, a 7.87% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2025-12-31 was $2.17M, a 3.14% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2025-09-30 was $2.13M, a 7.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2025 was $8.43M, a 89.75% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2024 was $4.44M, a 479.63% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2023 was $766.00K, a 751.11% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2022 was $90.00K.
| Period end | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 6 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 9 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.46M 10-Q · filed 2026-08-05 | $6.63M derived: sum of 3 quarters · filed 2026-08-05 | $8.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-06 | $4.38M derived: sum of 2 quarters · filed 2026-05-06 | $6.50M derived: sum of 3 quarters · filed 2026-05-06 | $8.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.29M derived: sum of 2 quarters · filed 2026-02-25 | $6.38M derived: sum of 3 quarters · filed 2026-08-05 | $8.43M 10-K · filed 2026-02-25 |
| 2025-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.21M derived: sum of 2 quarters · filed 2026-08-05 | $6.26M 10-Q · filed 2025-11-05 | $8.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.13M 10-Q · filed 2026-08-05 | $6.23M derived: sum of 3 quarters · filed 2026-08-05 | $8.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.05M 10-Q · filed 2026-05-06 | $4.15M derived: sum of 2 quarters · filed 2026-05-06 | $6.43M derived: sum of 3 quarters · filed 2026-05-06 | $6.46M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.39M derived: sum of 2 quarters · filed 2026-02-25 | $4.41M derived: sum of 3 quarters · filed 2026-02-25 | $4.44M 10-K · filed 2026-02-25 |
| 2024-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.31M derived: sum of 2 quarters · filed 2025-11-05 | $2.34M 10-Q · filed 2025-11-05 | $3.03M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $52.00K 10-Q · filed 2025-08-05 | $746.00K derived: sum of 3 quarters · filed 2026-02-25 | |
| 2024-03-31 | $26.00K 10-Q · filed 2025-05-05 | $720.00K derived: sum of 2 quarters · filed 2026-02-25 | ||
| 2023-12-31 | $694.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $766.00K 10-K · filed 2026-02-25 | ||
| 2023-09-30 | $72.00K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $90.00K 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |